Related Experiment Videos
Cefuroxime-induced immune hemolysis.
Colleen Ann Malloy1, Joseph E Kiss, Malliswari Challapalli
1Ronald McDonald Children's Hospital, Loyola University Medical Center, Department of Pediatrics, Maywood, Illinois 60153, USA.
The Journal of Pediatrics
|August 14, 2003
Summary
Drug-induced immune hemolytic anemia (IHA) is rare but increasingly reported, often linked to cephalosporin antibiotics. This study details the first reported case of IHA specifically associated with cefuroxime administration.
Area of Science:
- Hematology
- Pharmacology
- Immunology
Background:
- Drug-induced immune hemolytic anemia (IHA) is an uncommon but increasingly recognized adverse drug reaction.
- Second and third-generation cephalosporins are frequently implicated in drug-induced IHA.
- Understanding the specific agents causing IHA is crucial for patient safety.
Observation:
- This report presents the first documented case of IHA occurring after cefuroxime administration.
- Cefuroxime is a second-generation cephalosporin antibiotic.
- The patient developed hemolytic anemia following cefuroxime treatment.
Findings:
- Cefuroxime administration was directly associated with the development of immune hemolytic anemia.
- This case expands the known spectrum of cephalosporins capable of inducing IHA.
- The findings highlight the importance of considering cefuroxime as a potential cause of drug-induced IHA.
Implications:
- Clinicians should be aware of the potential for cefuroxime to cause IHA.
- This case underscores the need for vigilance in monitoring patients receiving cephalosporins for signs of hemolytic anemia.
- Further research may be warranted to elucidate the mechanisms underlying cefuroxime-induced IHA.